Market Cap 4.59B
Revenue (ttm) 0.00
Net Income (ttm) -246.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.41
Volume 1,119,300
Avg Vol 2,535,294
Day's Range N/A - N/A
Shares Out 102.01M
Stochastic %K 86%
Beta 0.61
Analysts Strong Sell
Price Target $47.33

Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively targ...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 259 3860
Address:
301 Binney Street, 3rd Floor, Cambridge, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:39 AM
Actionable Trade Alert for $SRRK: Market Context: $SRRK is currently trading at $45.2, near its 60D high of $45.5, indicating strong upward momentum. The RSI at 77.83 suggests overbought conditions, which could lead to a price correction. However, the stock has shown resilience, staying above its moving averages (MA30 at 34.82 and MA50 at 34.79), indicating a bullish trend. Directional Bias: Given the high RSI and proximity to the 60D high, we anticipate a potential pullback or consolidation before further upward movement. Trade Plan: - Suggested Entry: $45.2 - Stop Loss: $43.5 (approximately 3.8% below entry) - Take Profit Targets: 1. Target 1: $47.0 (4% gain) 2. Target 2: $50.0 (10% gain) 3. Target 3: $53.0 (17% gain) This plan offers a solid risk-reward ratio, with a potential ROI of over 17% on Target 3. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:14 PM
Actionable Trade Alert for $SRRK: Market Context: $SRRK is currently trading at $45.2, near its 60D high of $45.5, indicating strong upward momentum. The RSI at 77.83 suggests overbought conditions, which could lead to a price correction. However, the stock has shown resilience, staying above its moving averages (MA30 at 34.82 and MA50 at 34.79), indicating a bullish trend. Directional Bias: Given the high RSI and proximity to the 60D high, we anticipate a potential pullback or consolidation before further upward movement. Trade Plan: - Suggested Entry: $45.2 - Stop Loss: $43.5 (approximately 3.8% below entry) - Take Profit Targets: 1. Target 1: $47.0 (4% gain) 2. Target 2: $50.0 (10% gain) 3. Target 3: $53.0 (17% gain) This plan offers a solid risk-reward ratio, with a potential ROI of over 17% on Target 3. https://privateprofiteers.com
0 · Reply
Thinkingman91
Thinkingman91 Dec. 5 at 7:05 PM
$SRRK now we watch and see
0 · Reply
Thinkingman91
Thinkingman91 Dec. 5 at 7:04 PM
$SRRK 47.xx and change bet that’s the top until warrants are exercised
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Dec. 4 at 5:11 PM
$SRRK I'm still holding...
1 · Reply
MVL0502
MVL0502 Dec. 4 at 10:37 AM
$SRRK Per chatgpt: Implication for Takeover Potential - If apitegromab gets approved and launched in 2026, SRRK transforms from a pre-commercial biotech into a company with a first-in-class, muscle-targeting SMA therapy. That dramatically boosts its attractiveness to bigger pharma companies, especially those with neuromuscular / rare-disease portfolios. - Once manufacturing scale-up is achieved (through the second fill-finish facility), risk from the earlier CRL materially drops — making the risk/benefit equation more favorable for potential acquirers. - Therefore: the “takeover window” for SRRK is most likely to open in 2026 — ideally in the latter half, once commercial launch and initial market uptake begin (or even slightly before, if big-pharma firms move early).
1 · Reply
MVL0502
MVL0502 Dec. 4 at 10:35 AM
$SRRK Per chatgpt: here’s a plausible “best-case” and “base-case” scenario for when apitegromab might get approval / launch - Scenario / Milestone: Reinspection & FDA re-inspection of Catalent Indiana facility OR full qualification of second fill-finish site --Timing Estimate: By end of 2025 / early 2026 - Scenario / Milestone: Resubmission of BLA to FDA (assuming site cleared) -- Timing Estimate: Early 2026 - Scenario / Milestone: FDA review following resubmission -- Timing Estimate: If resubmitted early 2026 and granted priority review, approval could come within approximately 6 months after acceptance - Scenario / Milestone: U.S. commercial launch (if approved) -- Timing Estimate: Mid- to late-2026 - Scenario / Milestone: European launch (subject to EMA approval) --Timing Estimate: Potentially second half of 2026.
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 7:31 AM
Hedge Alert Live - Protect Your Portfolio Contract: $SRRK $40.00 Put · DEC 19, 2025 Exp Entry Price: $0.80 - $1.00 Exit Price Target: $1.92 Profit Margin: +140% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Thinkingman91
Thinkingman91 Dec. 3 at 6:30 PM
$SRRK if it clear $48 I know nuffin
1 · Reply
MaverikIT
MaverikIT Dec. 3 at 5:12 PM
$CLDX - eyeing 52wk$ ​ ​$APGE $SRRK @Doozio
0 · Reply
Latest News on SRRK
Scholar Rock to Present at Upcoming Investor Conferences

Nov 18, 2025, 8:00 AM EST - 19 days ago

Scholar Rock to Present at Upcoming Investor Conferences


Why Scholar Rock Stock Got Socked on Monday

Oct 13, 2025, 5:22 PM EDT - 7 weeks ago

Why Scholar Rock Stock Got Socked on Monday


Why Scholar Rock Stock Raced 6% Higher Today

Oct 9, 2025, 5:07 PM EDT - 2 months ago

Why Scholar Rock Stock Raced 6% Higher Today


US FDA declines to approve Scholar Rock's muscle weakness drug

Sep 23, 2025, 7:12 AM EDT - 2 months ago

US FDA declines to approve Scholar Rock's muscle weakness drug


Why Scholar Rock Stock Bounced Higher on Monday

Sep 15, 2025, 4:54 PM EDT - 2 months ago

Why Scholar Rock Stock Bounced Higher on Monday


Why Scholar Rock Stock Wilted on Wednesday

Aug 6, 2025, 5:10 PM EDT - 4 months ago

Why Scholar Rock Stock Wilted on Wednesday


Scholar Rock (SRRK) Q2 Loss Widens 63%

Aug 6, 2025, 4:54 PM EDT - 4 months ago

Scholar Rock (SRRK) Q2 Loss Widens 63%


Why Scholar Rock Shares Are Soaring Today

Jun 18, 2025, 1:41 PM EDT - 6 months ago

Why Scholar Rock Shares Are Soaring Today


Scholar Rock's drug helps preserve lean mass in mid-stage trial

Jun 18, 2025, 7:12 AM EDT - 6 months ago

Scholar Rock's drug helps preserve lean mass in mid-stage trial


Why Scholar Rock Stock Took a Knock on Monday

Apr 28, 2025, 7:08 PM EDT - 7 months ago

Why Scholar Rock Stock Took a Knock on Monday


Why Scholar Rock Holding Stock Topped the Market Today

Apr 23, 2025, 6:34 PM EDT - 8 months ago

Why Scholar Rock Holding Stock Topped the Market Today


Scholar Rock to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:15 PM EST - 10 months ago

Scholar Rock to Participate in Upcoming Investor Conferences


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:39 AM
Actionable Trade Alert for $SRRK: Market Context: $SRRK is currently trading at $45.2, near its 60D high of $45.5, indicating strong upward momentum. The RSI at 77.83 suggests overbought conditions, which could lead to a price correction. However, the stock has shown resilience, staying above its moving averages (MA30 at 34.82 and MA50 at 34.79), indicating a bullish trend. Directional Bias: Given the high RSI and proximity to the 60D high, we anticipate a potential pullback or consolidation before further upward movement. Trade Plan: - Suggested Entry: $45.2 - Stop Loss: $43.5 (approximately 3.8% below entry) - Take Profit Targets: 1. Target 1: $47.0 (4% gain) 2. Target 2: $50.0 (10% gain) 3. Target 3: $53.0 (17% gain) This plan offers a solid risk-reward ratio, with a potential ROI of over 17% on Target 3. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:14 PM
Actionable Trade Alert for $SRRK: Market Context: $SRRK is currently trading at $45.2, near its 60D high of $45.5, indicating strong upward momentum. The RSI at 77.83 suggests overbought conditions, which could lead to a price correction. However, the stock has shown resilience, staying above its moving averages (MA30 at 34.82 and MA50 at 34.79), indicating a bullish trend. Directional Bias: Given the high RSI and proximity to the 60D high, we anticipate a potential pullback or consolidation before further upward movement. Trade Plan: - Suggested Entry: $45.2 - Stop Loss: $43.5 (approximately 3.8% below entry) - Take Profit Targets: 1. Target 1: $47.0 (4% gain) 2. Target 2: $50.0 (10% gain) 3. Target 3: $53.0 (17% gain) This plan offers a solid risk-reward ratio, with a potential ROI of over 17% on Target 3. https://privateprofiteers.com
0 · Reply
Thinkingman91
Thinkingman91 Dec. 5 at 7:05 PM
$SRRK now we watch and see
0 · Reply
Thinkingman91
Thinkingman91 Dec. 5 at 7:04 PM
$SRRK 47.xx and change bet that’s the top until warrants are exercised
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Dec. 4 at 5:11 PM
$SRRK I'm still holding...
1 · Reply
MVL0502
MVL0502 Dec. 4 at 10:37 AM
$SRRK Per chatgpt: Implication for Takeover Potential - If apitegromab gets approved and launched in 2026, SRRK transforms from a pre-commercial biotech into a company with a first-in-class, muscle-targeting SMA therapy. That dramatically boosts its attractiveness to bigger pharma companies, especially those with neuromuscular / rare-disease portfolios. - Once manufacturing scale-up is achieved (through the second fill-finish facility), risk from the earlier CRL materially drops — making the risk/benefit equation more favorable for potential acquirers. - Therefore: the “takeover window” for SRRK is most likely to open in 2026 — ideally in the latter half, once commercial launch and initial market uptake begin (or even slightly before, if big-pharma firms move early).
1 · Reply
MVL0502
MVL0502 Dec. 4 at 10:35 AM
$SRRK Per chatgpt: here’s a plausible “best-case” and “base-case” scenario for when apitegromab might get approval / launch - Scenario / Milestone: Reinspection & FDA re-inspection of Catalent Indiana facility OR full qualification of second fill-finish site --Timing Estimate: By end of 2025 / early 2026 - Scenario / Milestone: Resubmission of BLA to FDA (assuming site cleared) -- Timing Estimate: Early 2026 - Scenario / Milestone: FDA review following resubmission -- Timing Estimate: If resubmitted early 2026 and granted priority review, approval could come within approximately 6 months after acceptance - Scenario / Milestone: U.S. commercial launch (if approved) -- Timing Estimate: Mid- to late-2026 - Scenario / Milestone: European launch (subject to EMA approval) --Timing Estimate: Potentially second half of 2026.
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 7:31 AM
Hedge Alert Live - Protect Your Portfolio Contract: $SRRK $40.00 Put · DEC 19, 2025 Exp Entry Price: $0.80 - $1.00 Exit Price Target: $1.92 Profit Margin: +140% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Thinkingman91
Thinkingman91 Dec. 3 at 6:30 PM
$SRRK if it clear $48 I know nuffin
1 · Reply
MaverikIT
MaverikIT Dec. 3 at 5:12 PM
$CLDX - eyeing 52wk$ ​ ​$APGE $SRRK @Doozio
0 · Reply
MaverikIT
MaverikIT Dec. 3 at 5:10 PM
@Doozio $SRRK +2.53 - eyeing 52wk$
0 · Reply
Sillyspuh
Sillyspuh Dec. 3 at 4:08 PM
$SRRK Nice
0 · Reply
Bulldog344
Bulldog344 Dec. 3 at 2:29 AM
$SRRK antagonism of myostatin
0 · Reply
Bulldog344
Bulldog344 Dec. 2 at 4:17 PM
$SRRK taking a position
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 1 at 10:25 PM
Hedge Alert Live - Protect Your Portfolio Contract: $SRRK $40.00 Put · DEC 19, 2025 Exp Entry Price: $1.40 - $1.45 Exit Price Target: $2.60 Profit Margin: +86% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Doozio
Doozio Nov. 29 at 4:46 PM
$SRRK huckleberries n $$$$ patterns as only faaatch 💣s can stop da 🧠 spread if da huckleberries don’t $FOLD 🐒🍌🧠⏰♾️
1 · Reply
Tdorsey1776
Tdorsey1776 Nov. 28 at 2:45 PM
$VRDN $SNDX $SRRK $NVCR $CADL Thankful for the bio resurgence, expecting 2026 to be a very active M&A environment. Bio is cyclical and we are in early stages of would could be massive feeding frenzy. GLTA
0 · Reply
Reapthewhirlwind69
Reapthewhirlwind69 Nov. 26 at 7:34 PM
$SRRK This thing is a TANK!
1 · Reply
Reapthewhirlwind69
Reapthewhirlwind69 Nov. 26 at 3:13 PM
$SRRK Steady Grind!
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 26 at 2:40 AM
Hedge Alert Live - Protect Your Portfolio Contract: $SRRK $40.00 Put · DEC 19, 2025 Exp Entry Price: $2.00 - $2.20 Exit Price Target: $3.42 Profit Margin: +71% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Thinkingman91
Thinkingman91 Nov. 25 at 5:34 PM
$SRRK another successful target, I’m even getting better at timing which has always been an issue
1 · Reply
JohnTill
JohnTill Nov. 25 at 3:03 PM
$SRRK I will very likely regret it but my price target of 42.8 is in and I am out on my other 50% just now. Overall the trade was good for 50% (loaded at $28) and was my second largest position so very decent clip. Good luck to those long and will revisit and hopefully my opinion on a buyout does not occur until I am back in again.
1 · Reply